0 Evaluaciones

ID

42996

Descripción

Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) See http://clinicaltrials.gov/ct2/show/record/NCT00661609

Link

http://clinicaltrials.gov/ct2/show/record/NCT00661609

Palabras clave

  1. 18/11/11 18/11/11 -
  2. 26/3/14 26/3/14 - Martin Dugas
  3. 17/9/21 17/9/21 -
Subido en

17 de septiembre de 2021

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :


    Sin comentarios

    Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

    Eligibility DRKS00004052 NCT00661609 Bladder Cancer

    Eligibility Advanced Bladder Cancer NCT00661609

    Inclusion criteria
    Descripción

    Inclusion criteria

    Alias
    UMLS CUI-1
    C1512693 (Inclusion)
    Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra)
    Descripción

    Urothelial Neoplasm

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C1519840 (Urothelial Neoplasm)
    Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
    Descripción

    Stage IV

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C0441772 (Stage level 4)
    SNOMED
    258228008
    LOINC
    LA6386-2
    Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting
    Descripción

    Prior chemotherapy

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C1514457 (Prior Chemotherapy)
    Ambulatory and capable of all selfcare more than 50% of waking hours
    Descripción

    General status

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C0947124 (General status)
    LOINC
    LP29998-9
    Exclusion criteria
    Descripción

    Exclusion criteria

    Alias
    UMLS CUI-1
    C0680251 (Exclusion Criteria)
    Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication, 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
    Descripción

    Prior treatment

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C1514463 (Prior Therapy)
    Inadequate bone marrow reserve
    Descripción

    Inadequate bone marrow reserve

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    CL406855 (undefined)
    Inadequate liver function in the presence of liver metastases
    Descripción

    Liver Dysfunction

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C0086565 (Liver Dysfunction)
    SNOMED
    75183008
    Impaired renal function
    Descripción

    Impaired renal function

    Tipo de datos

    boolean

    Alias
    UMLS CUI-1
    C1565489 (Renal Insufficiency)
    SNOMED
    236423003

    Similar models

    Eligibility Advanced Bladder Cancer NCT00661609

    Name
    Tipo
    Description | Question | Decode (Coded Value)
    Tipo de datos
    Alias
    Item Group
    Inclusion criteria
    C1512693 (UMLS CUI-1)
    Urothelial Neoplasm
    Item
    Confirmed urothelial cancer (cancer of the bladder, renal pelvis, ureter, or urethra)
    boolean
    C1519840 (UMLS CUI-1)
    Stage IV
    Item
    Tumor, Node, Metastasis (TNM) Stage IV urothelial cancer that can not be helped by curative surgery and/or curative radiotherapy
    boolean
    C0441772 (UMLS CUI-1)
    Prior chemotherapy
    Item
    Must have had a maximum of 2 prior chemotherapeutic regimens, one for unremovable and/or metastasized disease, and the other in the adjuvant or neo-adjuvant setting
    boolean
    C1514457 (UMLS CUI-1)
    General status
    Item
    Ambulatory and capable of all selfcare more than 50% of waking hours
    boolean
    C0947124 (UMLS CUI-1)
    Item Group
    Exclusion criteria
    C0680251 (UMLS CUI-1)
    Prior treatment
    Item
    Prior treatment with investigational or standard anti-cancer agents, including radiotherapy, within 4 weeks prior to first dose of study medication, 6 weeks if prior systemic mitomycin, nitrosourea, or suramin.
    boolean
    C1514463 (UMLS CUI-1)
    Inadequate bone marrow reserve
    Item
    Inadequate bone marrow reserve
    boolean
    CL406855 (UMLS CUI-1)
    Liver Dysfunction
    Item
    Inadequate liver function in the presence of liver metastases
    boolean
    C0086565 (UMLS CUI-1)
    Impaired renal function
    Item
    Impaired renal function
    boolean
    C1565489 (UMLS CUI-1)

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial